FDA Peptide Reclassification 2026 Amanecia Health AOD 9604 Peptide: Fat Loss, Before and After Results, and How It Works The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Watson responsible for AOD 9604 use, says WADA boss Fahey Peptides Might Be Making a Comeback In 2023, the FDA restricted 19 peptides from compounding pharmacies. Now, regulators are reviewing a possible reversal, which could allow 14 of those peptides to